Dündar, BetülDinçgez Çakmak, BurcuÖzgen, GültenKetenci Gencer, FatmaAydın Boyama, Burcu2022-04-132022-04-132017Dündar, B., Dinçgez Çakmak, B., Özgen, G., Ketenci Gencer, F. ve Aydın Boyama, B. (2017). Severe bone marrow suppression following single-dose methotrexate treatment for ectopic pregnancy. The European Research Journal, 3(3), 285-289. https://doi.org/10.18621/eurj.304373https://doi.org/10.18621/eurj.304373https://hdl.handle.net/20.500.12511/9326Methotrexate is associated with multisystem side effects which depend on the dosage, route of administration and length of treatment. Bone marrow suppression is a very rare but one of the most mortal complications. A case of severe bone marrow suppression following single dose methotrexate for ectopic pregnancy was presented in this study. A 33-year-old woman, diagnosed as ectopic pregnancy, was given single-dose intramuscular methotrexate of 50 mg/m². On 10th day patient was admitted with lethargy, irritability, vomiting, hematemesis, diarrhea, oral mucositis and skin rash. Laboratory findings revealed severe bone marrow suppression. Supportive treatment together with antibacterial/ antifungal drugs and granulocyte colony stimulating factors were administered. On the 3rd day of treatment, mucositis and oral intake began to improve. After 1 week complete blood count was normal. Methotrexate may have mortal clinical consequences even with very low doses. Therefore, a careful patient history for patient selection and closer clinical follow-up are essential.eninfo:eu-repo/semantics/openAccessBone Marrow SuppressionEctopic PregnancyMethotrexateSide EffectsSingle-Dose RegimenArticle3328528910.18621/eurj.304373TWprek1UZzNOdz09